---
title: "Ironwood Pharmaceuticals' LINZESS Secures FDA Approval For Functional Constipation Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287788765.md"
description: "Ironwood Pharmaceuticals, Inc. (IRWD) announced FDA approval for LINZESS (linaclotide) to treat functional constipation in pediatric patients aged 2 and older. This makes LINZESS the only FDA-approved prescription therapy for this condition. The approval is based on a Phase 3 clinical trial showing improved bowel movement frequency. IRWD shares are currently trading at $3.98, up 2.18% on Nasdaq."
datetime: "2026-05-27T14:43:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287788765.md)
  - [en](https://longbridge.com/en/news/287788765.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287788765.md)
---

# Ironwood Pharmaceuticals' LINZESS Secures FDA Approval For Functional Constipation Treatment

Add  as your preferred news source on Google

 Add Now

Wednesday, Ironwood Pharmaceuticals, Inc. (IRWD) announced that the U.S. Food and Drug Administration has approved the use of LINZESS, also known as linaclotide, in pediatric patients 2 years of age and older with functional constipation.

With this approval, LINZESS remains the only FDA-approved prescription therapy for pediatric functional constipation, a chronic condition characterized by hard, infrequent bowel movements.

The approval is backed by data from a 12-week Phase 3 randomized, placebo-controlled clinical trial, which demonstrated improvement in spontaneous bowel movement frequency compared with placebo.

Currently, IRWD is trading at $3.98, up 2.18 percent on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [IRWD.US](https://longbridge.com/en/quote/IRWD.US.md)

## Related News & Research

- [REG - Tooru PLC - OAF and Pulsin Update](https://longbridge.com/en/news/293727121.md)
- [Phoenix Children's Foundation Halves Its Prospecting Time with ZoomInfo | GTM Stock News](https://longbridge.com/en/news/293788761.md)
- [Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall?](https://longbridge.com/en/news/294229928.md)
- [B Capital invests in pediatric behavioral health provider Flourish Health](https://longbridge.com/en/news/294365281.md)
- [Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology](https://longbridge.com/en/news/294366513.md)